Telephone
61.3.9629.5566
Address
Level 15 500 Collins Street Melbourne, Victoria (VIC) 3000
Description
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.38 - 1.68
Trade Value (12mth)
AU$151,590.00
1 week
1.28%
1 month
-8.14%
YTD
-71.4%
1 year
-71.99%
All time high
4.3453
EPS 3 yr Growth
195.200%
EBITDA Margin
%
Operating Cashflow
-$45m
Free Cash Flow Return
-93.50%
ROIC
-107.40%
Interest Coverage
-3,597.80
Quick Ratio
4.90
Shares on Issue (Fully Dilluted)
290m
HALO Sector
Healthcare
Next Company Report Date
23-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
1.28
Date | Announcements |
---|---|
31 October 23 |
PAR Successful Placement and Fully Underwritten ANREO
×
PAR Successful Placement and Fully Underwritten ANREO |
31 October 23 |
Replacement Entitlement Offer and Placement Prospectus
×
Replacement Entitlement Offer and Placement Prospectus |
31 October 23 |
Update - Proposed issue of securities - PAR
×
Update - Proposed issue of securities - PAR |
31 October 23 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 March 23 |
Trading Halt
×
Trading Halt |
31 July 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 23 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
31 January 22 |
Quarterly Update and Appendix 4C - quarterly
×
Quarterly Update and Appendix 4C - quarterly |
30 September 22 |
Trading Halt
×
Trading Halt |
30 October 23 |
Trading Halt
×
Trading Halt |
30 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 October 23 |
Paradigm Launches $30M Capital Raising
×
Paradigm Launches $30M Capital Raising |
30 October 23 |
Investor Presentation - $30m Capital Raise
×
Investor Presentation - $30m Capital Raise |
30 October 23 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
30 October 23 |
Entitlement Offer and Placement Prospectus
×
Entitlement Offer and Placement Prospectus |
30 October 23 |
Update - Proposed issue of securities - PAR
×
Update - Proposed issue of securities - PAR |
30 October 15 |
CEO AGM Presentation
×
CEO AGM Presentation |
30 November 23 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
30 November 23 |
Notification of cessation of securities - PAR
×
Notification of cessation of securities - PAR |
30 November 23 |
Change of Director's Interest Notice - Rennie
×
Change of Director's Interest Notice - Rennie |
30 November 16 |
Managing Director's Presentation to AGM
×
Managing Director's Presentation to AGM |
30 November 16 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
30 May 22 |
Paradigm Appoints Experienced US-Based CEO
×
Paradigm Appoints Experienced US-Based CEO |
30 June 22 |
Paradigm Reports Australian Patent Acceptance
×
Paradigm Reports Australian Patent Acceptance |
30 December 22 |
Notification of cessation of securities - PAR
×
Notification of cessation of securities - PAR |
30 August 22 |
Paradigm Appoints Interim Company Secretary
×
Paradigm Appoints Interim Company Secretary |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.